Avecho Biotechnology (ASX:AVE) Research & Development: A$2.07 Mil (TTM As of Dec. 2025)


What is Avecho Biotechnology Research & Development?

Avecho Biotechnology ASX:AVE Research & Development is A$2.07 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Avecho Biotechnology's Research & Development for the six months ended in Dec. 2025 was A$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.07 Mil.

Avecho Biotechnology  (ASX:AVE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Avecho Biotechnology Research & Development Related Terms

Avecho Biotechnology Research & Development Historical Data

* Premium members only.

The historical data trend for Avecho Biotechnology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avecho Biotechnology Research & Development Chart

Avecho Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.55 1.59 1.47 3.59 0.00

Avecho Biotechnology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 1.91 1.68 2.07 0.00

Avecho Biotechnology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$2.07 Mil mean?
Avecho Biotechnology (ASX:AVE) has a Research & Development of A$2.07 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Avecho Biotechnology and its competitors.
Is Avecho Biotechnology's Research & Development too high?
Avecho Biotechnology's current Research & Development is A$2.07 Mil.
How does Avecho Biotechnology's Research & Development compare to VRTX and REGN?
Avecho Biotechnology's Research & Development of A$2.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Avecho Biotechnology and its competitors. Avecho Biotechnology's current Research & Development is A$2.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current Research & Development of A$2.07 Mil. The current Research & Development is A$2.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current Research & Development is A$2.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avecho Biotechnology Business Description

Other Exchanges OEZ:Germany
Address Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.